$JNJ Company News Why you should favor large-cap stocks

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:55 AM

$JNJ Company News

Why you should favor large-cap stocks for the next six weeks 5:50 a.m. Today - Mark Hulbert
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Republican victory will boost these 21 stocks 7:45 a.m. Nov. 5, 2014 - Michael Brush
Ebola play Halyard Health stock gains are modest 1:02 p.m. Nov. 3, 2014 - Russ Britt
Ebola-nation travelers to U.S. to be watched 21 days 3:04 p.m. Oct. 22, 2014 - Russ Britt
Johnson & Johnson to begin testing Ebola vaccine in January 9:14 a.m. Oct. 22, 2014 - Jonathan D. Rockoff
A possible new Ebola vaccine from Johnson&Johnson 4:32 a.m. Oct. 22, 2014 - MarketWatch
Fighting Ebola though investing: one firm’s approach 6:42 p.m. Oct. 21, 2014 - Wallace Witkowski
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
Updates, advisories and surprises 5:31 p.m. Oct. 14, 2014 - MarketWatch
Delta, Citigroup gain; J.P. Morgan, Wells Fargo slide following results 10:58 a.m. Oct. 14, 2014 - Sue Chang
Newscast: Google launches same-day delivery 9:58 a.m. Oct. 14, 2014 - MarketWatch
All the reasons to sell this market are enough to draw a guy in 9:23 a.m. Oct. 14, 2014 - Shawn Langlois
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Johnson & Johnson shares gain after profit beat, raised outlook 7:59 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson shares up 1% premarket after Q3 results 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson ups 2014 EPS outlook to $5.92-$5.97 from $5.85-$5.92 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 net EPS $1.66 vs. $1.04 a year ago 7:49 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales of $18.5 bln vs. FactSet consensus $18.44 bln 7:48 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales up 5.1% from last year to $18.5 bln 7:47 a.m. Oct. 14, 2014 - Tomi Kilgore

Stock Market Today: Stocks Fluctuate as Fed Rate Hike Worries Trump Retail Sales 18 min ago - TheStreet.com
What Licensing Imetelstat Will Mean for Geron 10:45 a.m. Today - 247WallSt.com
Setting Up A Portfolio That Millennials Can Relate To 10:05 a.m. Today - Seeking Alpha
The Post AASLD Annual Meeting Hepatitis C Landscape 6:15 a.m. Today - Seeking Alpha
Geron wins deal to develop blood disorder drug, could get $935M 5:55 p.m. Nov. 13, 2014 - Seeking Alpha
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog 5:10 p.m. Nov. 13, 2014 - Zacks.com
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson 4:34 p.m. Nov. 13, 2014 - TheStreet.com
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak 4:24 p.m. Nov. 13, 2014 - Seeking Alpha
Total Return And Dividend Growth Investing 3:50 p.m. Nov. 13, 2014 - Seeking Alpha
Mallinckrodt Says FDA Reclassified ADHD Generic Drug 1:21 p.m. Nov. 13, 2014 - The Wall Street Journal Interactive Edition
Does The End Of QE Portend A New Beginning For Income Investors? 12:48 p.m. Nov. 13, 2014 - Seeking Alpha
Tracking Tweedy Browne Portfolio - Q3 2014 Update 11:14 a.m. Nov. 13, 2014 - Seeking Alpha
FDA clears label expansion for Janssen antipsychotic 10:53 a.m. Nov. 13, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: JPM, JNJ, PG 10:29 a.m. Nov. 13, 2014 - TheStreet.com
Mallinckrodt ADHD Drug Hits FDA Trouble; Stock Drops 10:09 a.m. Nov. 13, 2014 - Investors Business Daily
FDA downgrades classification of Mallinckrodt's ADHD med 7:33 a.m. Nov. 13, 2014 - Seeking Alpha
Successful Dividend Investing Requires Patience 2:48 a.m. Nov. 13, 2014 - Seeking Alpha
Margin Of Safety: More Than Just Price 12:34 a.m. Nov. 13, 2014 - Seeking Alpha
The Problem With "Just Exchanging Your Shares" 12:25 a.m. Nov. 13, 2014 - Seeking Alpha
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog 5:00 p.m. Nov. 12, 2014 - Zacks.com

Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors 9:00 a.m. Today - PR Newswire - PRF
Amcor Rigid Plastics Renews National Sponsorshipof America Recycles Day 2014 7:29 p.m. Nov. 11, 2014 - BusinessWire - BZX
La Lumiere Closes $20 Million Series B Financing 8:02 a.m. Nov. 11, 2014 - PR Newswire - PRF
CORRECTING and REPLACING Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM 7:40 p.m. Nov. 10, 2014 - BusinessWire - BZX
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 9:23 a.m. Nov. 10, 2014 - ACCESSWIRE
HackerAgency Names New Director of Strategic Planning; Adds Senior Client Leadership 8:35 a.m. Nov. 10, 2014 - PR Newswire - PRF
Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM 8:03 a.m. Nov. 10, 2014 - BusinessWire - BZX
New President and New Offices Signal New Era for New Jersey-based BNO 6:36 p.m. Nov. 7, 2014 - PR Newswire - PRF
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition 4:05 p.m. Nov. 7, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting 4:20 p.m. Nov. 6, 2014 - Marketwired
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50 9:26 a.m. Nov. 5, 2014 - ACCESSWIRE
Baron and Budd Investigating Potential Xarelto Lawsuits 4:03 p.m. Nov. 4, 2014 - BusinessWire - BZX
Legal-Bay Lawsuit Settlement Funding Updates News on All Major Hip Litigations 5:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Coronary Stents Market (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019 8:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan 1:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire 9:15 a.m. Oct. 30, 2014 - PR Newswire - PRF
Johnson & Johnson Diabetes Solutions Companies Join The Joslin Institute for Technology Translation (JITT) As Founding Members 9:00 a.m. Oct. 30, 2014 - BusinessWire - BZX
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation 5:15 a.m. Oct. 29, 2014 - Thomson Reuters ONE
Johnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances 4:00 p.m. Oct. 28, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...